<![CDATA[ReNAgade Therapeutics 보도자료 - 뉴스와이어]]>https://www.newswire.co.kr/?md=A10&act=article&no=43244>Thu, 16 Apr 2026 10:35:51 +0900Copyright (c) 2004~2026 Korea Newswire All rights reservedko-KR<![CDATA[CORRECTING and REPLACING ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology]]>https://www.newswire.co.kr/newsRead.php?no=988750Sun, 28 Apr 2024 11:40:00 +0900<![CDATA[레니게이드 테라퓨틱스, 간나 바이오 및 글리칸 생물학에 대한 노력 계속]]>https://www.newswire.co.kr/newsRead.php?no=988752Sun, 28 Apr 2024 11:40:00 +0900<![CDATA[ReNAgade Therapeutics Announces Presentations at the ASGCT 27th Annual Meeting]]>https://www.newswire.co.kr/newsRead.php?no=988431Wed, 24 Apr 2024 09:30:00 +0900<![CDATA[레니게이드 테라퓨틱스, ASGCT 27차 연례 회의에서 프레젠테이션 계획 발표]]>https://www.newswire.co.kr/newsRead.php?no=988437Wed, 24 Apr 2024 09:30:00 +0900<![CDATA[ReNAgade Therapeutics Appoints Joe Bolen, Ph.D., Chief Science Innovation Officer]]>https://www.newswire.co.kr/newsRead.php?no=985021Wed, 28 Feb 2024 12:05:00 +0900<![CDATA[레니게이드 테라퓨틱스, 최고 과학 혁신 책임자로 조 볼렌 박사 임명]]>https://www.newswire.co.kr/newsRead.php?no=985022Wed, 28 Feb 2024 12:05:00 +0900<![CDATA[ReNAgade Therapeutics to Present at the Evercore ISI 2024 Emerging Biotech Conference]]>https://www.newswire.co.kr/newsRead.php?no=984762Fri, 23 Feb 2024 14:10:00 +0900<![CDATA[레니게이드 테라퓨틱스, 에버코어 ISI 2024 이머징 바이오텍 콘퍼런스에서 발표 예정]]>https://www.newswire.co.kr/newsRead.php?no=984763Fri, 23 Feb 2024 14:10:00 +0900<![CDATA[ReNAgade to Present at the Upcoming 42nd Annual J.P. Morgan Healthcare Conference]]>https://www.newswire.co.kr/newsRead.php?no=982181Fri, 05 Jan 2024 11:15:00 +0900<![CDATA[리나게이드, 제42차 J.P. 모건 헬스케어 콘퍼런스에서 발표 예정]]>https://www.newswire.co.kr/newsRead.php?no=982182Fri, 05 Jan 2024 11:15:00 +0900<![CDATA[ReNAgade Therapeutics Appoints Paul Perreault to Board of Directors]]>https://www.newswire.co.kr/newsRead.php?no=980474Thu, 07 Dec 2023 14:30:00 +0900<![CDATA[리나게이드 테라퓨틱스, 폴 페로를 이사회에 임명]]>https://www.newswire.co.kr/newsRead.php?no=980476Thu, 07 Dec 2023 14:30:00 +0900<![CDATA[ReNAgade Therapeutics to Present Preclinical Data Demonstrating Potent Extra-Hepatic Delivery of mRNA Using Proprietary Lipid Nanoparticles at 11th International mRNA Health Conference]]>https://www.newswire.co.kr/newsRead.php?no=977627Tue, 31 Oct 2023 16:25:00 +0900<![CDATA[레니게이드 테라퓨틱스, 제11회 국제 mRNA 헬스 콘퍼런스에서 독점 지질 나노입자를 사용한 mRNA 간외 전달 효능을 입증하는 전임상 데이터 발표]]>https://www.newswire.co.kr/newsRead.php?no=977629Tue, 31 Oct 2023 16:25:00 +0900<![CDATA[ReNAgade Therapeutics Named to the 2023 Endpoints 11]]>https://www.newswire.co.kr/newsRead.php?no=975034Fri, 22 Sep 2023 10:25:00 +0900<![CDATA[레니게이드 테라퓨틱스, 2023년 엔드포인트 11에 선정]]>https://www.newswire.co.kr/newsRead.php?no=975035Fri, 22 Sep 2023 10:25:00 +0900<![CDATA[ReNAgade Therapeutics Appoints Laurie Stelzer as Chief Financial Officer]]>https://www.newswire.co.kr/newsRead.php?no=974346Thu, 14 Sep 2023 09:45:00 +0900<![CDATA[리나게이드 테라퓨틱스, 최고재무책임자에 로리 스텔저 임명]]>https://www.newswire.co.kr/newsRead.php?no=974348Thu, 14 Sep 2023 09:45:00 +0900<![CDATA[ReNAgade Therapeutics Launches with over $300 Million in Series A Financing To Unlock the Limitless Potential of RNA Medicine]]>https://www.newswire.co.kr/newsRead.php?no=967498Wed, 24 May 2023 15:30:00 +0900<![CDATA[리나게이드 테라퓨틱스, RNA 의약품의 무한한 잠재력을 실현하기 위해 3억달러 이상의 시리즈 A 파이낸싱 론칭]]>https://www.newswire.co.kr/newsRead.php?no=967499Wed, 24 May 2023 15:30:00 +0900